Pfizer Inc. (ETR:PFE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 116.37B |
| Revenue (ttm) | 57.67B |
| Net Income (ttm) | 7.28B |
| Shares Out | n/a |
| EPS (ttm) | 1.28 |
| PE Ratio | 15.99 |
| Forward PE | 8.00 |
| Dividend | 1.57 (7.91%) |
| Ex-Dividend Date | May 9, 2025 |
| Volume | 102,991 |
| Average Volume | 118,842 |
| Open | 20.45 |
| Previous Close | 20.43 |
| Day's Range | 19.78 - 20.48 |
| 52-Week Range | 18.57 - 29.50 |
| Beta | 0.50 |
| RSI | 39.45 |
| Earnings Date | Apr 29, 2025 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial numbers in USD Financial StatementsNews
Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer
Commission's Pfizergate loss hailed as ‘victory for transparency’
The EU Court ruled against the Commission for failing to justify its refusal to release texts between von der Leyen and Pfizer’s CEO. Critics say the Commission’s actions undermine public trust and ac...
Commission moves top lawyer to Spain in wake of Pfizergate defeat
In their announcement, the Commission made no reference to their legal defeat just hours prior.
Parliament celebrates Pfizer decision as victory against Commission’s secrecy
After an EU court ruled that Ursula von der Leyen should have published text messages she exchanged with the CEO of Pfizer, MEPs across all party lines have welcomed the decision as a victory against ...
Pfizer: Bearish Catalysts Brewing
EU’s Von der Leyen loses court case over secret Pfizer texts
Wednesday’s ruling is likely to affect how the EU’s executive arm treats text messages in the future.
Von der Leyen’s texts with Pfizer boss can be shared, says EU’s highest court
European Court of Justice says no ‘plausible explanation’ given for denying New York Times access to texts from pandemic The EU’s highest court has cancelled a decision to withhold Ursula von der Leye...
EU Commission wrong to block access to texts between Ursula von der Leyen and Pfizer CEO, ECJ rules
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albe...
EU Commission loses on all counts in Pfizergate legal case
The EU’s top court annulled the Commission’s decision to deny the newspaper New York Times access to messages exchanged between President Ursula von der Leyen and Pfizer CEO Albert Bourla, finding tha...
Pfizergate: Commission broke transparency rules over von der Leyen texts, court rules
The European Commission wrongly dismissed a journalist's request to access texts between the president and the Pfizer CEO, the court said.
EU court annuls rejection of bid for EU's von der Leyen vaccine messages with Pfizer
Europe's second-top court on Wednesday dismissed the European Commission's rejection of a New York Times' request to access text messages between its President Ursula von der Leyen and Pfizer CEO Albe...
Pfizer, Eli Lilly, and Other Pharma Stocks Fall. Questions Remain About Trump's Executive Order.
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved drugs, analysts say.
Pfizergate and von der Leyen’s political long Covid
A four-year saga will reach its climax on Wednesday, but the Commission president is likely to emerge relatively unscathed.
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock
On CNBC's “ Mad Money Lightning Round ,” Jim Cramer recommended buying Energy Transfer LP (NYSE: ET). “The pipes are a great business here, they really are,” he added . On the earnings front, Energy ...
NVO, PFE and LLY Forecast – Pharma Stocks React to Drug Order Trump Signs
The executive order that Donald Trump has signed over the last 24 hours could have a significant effect on pharmaceutical companies, and as a result, we should be paying attention to this sector.
Lightning Round: Devon Energy has been a nightmare, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Energy Transfer, Harrow, Pfizer, Kinsale, Manulife Financial, Iron Mountain, and ADT.
50 Fortune World's Most Admired Companies (FWMAC): 24 "Safer", 1 Ideal Buy
Fortune and Korn Ferry's survey identified the top 50 Most Admired Companies, focusing on criteria like investment value, management quality, and social responsibility. Four dividend-paying companies,...
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
President Trump's EO to lower drug prices is the beginning of a long process, says Jeff Jonas
Jeff Jonas, Gabelli Funds portfolio manager, joins CNBC's 'Power Lunch' to discuss reactions to President Trump's executive order to lower drug prices, the impact to pharma companies, and more.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.